Connect with us

Life Sciences

Densitas Connects to Nuance Precision Imaging Network to Empower Collaborative Care Teams and Improve Patient Outcomes with Workflow-Integrated AI

Densitas Inc., a global provider of AI solutions for digital mammography and breast screening, announced that it has connected to the Nuance Precision…

Published

on

This article was originally published by AITHORITY
Densitas Connects to Nuance Precision Imaging Network to Empower Collaborative Care Teams and Improve Patient Outcomes with Workflow-Integrated AI

Densitas Inc., a global provider of AI solutions for digital mammography and breast screening, announced that it has connected to the Nuance Precision Imaging Network (PIN), a secure nationwide cloud platform empowering collaborative care teams with streamlined communications and workflow-integrated AI insights from diagnostic imaging to improve healthcare outcomes and costs.

Densitas intelliMammo, comprising intelliMammo densityAI, qualityAI, and riskAI, offers a FDA/ACR compliant solution for clinical and enterprise decision-making that includes breast density, breast cancer risk, and clinical image quality. IntelliMammo presents clinical care teams with on-demand actionable information and digitized workflows to systematically improve mammography quality, organizational and workflow efficiencies, and support early breast cancer detection and treatment.

Recommended AI: Consider Your DOOH Buying Methods Wisely: Direct Sales vs. Programmatic Buying

Leveraging the nationwide scale of the Nuance PowerScribe and Nuance PowerShare diagnostic imaging solutions, the Nuance Precision Imaging Network connects radiologists, providers, health plans, self-insured employers, life science companies, and other imaging stakeholders to broaden access to precision diagnostics and therapeutics, increase healthcare efficiency, and lower costs. It enables secure and seamless sharing of AI insights from diagnostic imaging to enhance clinical decision-making, enhance care team collaboration, and facilitate the earlier detection and treatment of diseases for improved patient outcomes.

“Our intelliMammo platform provides a solid foundation for population health management as patients navigate through breast cancer screening, diagnostic, treatment, and prevention pathways,” said Mo Abdolell, CEO, of Densitas. “Through the Nuance Precision Imaging Network, intelliMammo becomes immediately accessible to over 10,000 healthcare facilities across the US. The addition of intelliMammo opens the door to Nuance customers to capture information from routine screening mammograms and seamlessly leverage patient-centered data and insights in their existing clinical and administrative workflows.”

“We’re proud to support Densitas with seamless workflow-integrated access through the Nuance Precision Imaging Network, providing powerful clinical decision support tools at the point-of-care as they advance their important work in breast cancer screening,” said Roland Dias, Vice President, Precision Imaging Network, Nuance.

Recommended AI: Understanding the Role of AI in Gaming

[To share your insights with us, please write to sghosh@martechseries.com]

The post Densitas Connects to Nuance Precision Imaging Network to Empower Collaborative Care Teams and Improve Patient Outcomes with Workflow-Integrated AI appeared first on AiThority.

diagnostics
therapeutics


Life Sciences

Wittiest stocks:: Avalo Therapeutics Inc (NASDAQ:AVTX 0.00%), Nokia Corp ADR (NYSE:NOK 0.90%)

There are two main reasons why moving averages are useful in forex trading: moving averages help traders define trend recognize changes in trend. Now well…

Continue Reading
Life Sciences

Spellbinding stocks: LumiraDx Limited (NASDAQ:LMDX 4.62%), Transocean Ltd (NYSE:RIG -2.67%)

There are two main reasons why moving averages are useful in forex trading: moving averages help traders define trend recognize changes in trend. Now well…

Continue Reading
Life Sciences

Asian Fund for Cancer Research announces Degron Therapeutics as the 2023 BRACE Award Venture Competition Winner

The Asian Fund for Cancer Research (AFCR) is pleased to announce that Degron Therapeutics was selected as the winner of the 2023 BRACE Award Venture Competition….

Continue Reading

Trending